IL33 and neoplasm: Studies in APC-mutant mice found that decreased tumour burden upon IL-33-deficiency (but not IL-25-deficiency) is associated with reduced tumour mast cells (81, 84), suggesting a potential pro-tumoral role downstream IL-33 signalling.